Estrogen replacement therapy and breast cancer survival in a large screening study

Journal of the National Cancer Institute

Volumn 91, Issue 3, 1999, Pages 264-270

  Schairer, Catherine ^a,c   Gail, Mitchell ^a   Byrne, Celia ^b   Rosenberg, Philip S ^a   Sturgeon, Susan R ^a   Brinton, Louise A ^a   Hoover, Robert N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DRUG UTILIZATION; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; UTILIZATION REVIEW;

EID: 0033518617     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.3.264     Document Type: Article

References (31)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350: 1047-59.
2. Hunt K. Vessey M. McPherson K. Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94:620-35.
3. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
4. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151: 75-8.
5. Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Cancer Causes Control 1993; 4:369-74.
6. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6: 227-31.
7. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67: 327-32.
8. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7: 449-57.
9. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women [published erratum appears in JAMA 1991;265:1828]. JAMA 1990;264: 2648-53.
10. Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3: 433-9.
11. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-8.
12. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M. et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
13. Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 1991;49:526-30.
14. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80:400-4.
15. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-7.
16. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38: 325-34.
17. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277: 1140-7.
18. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825-32.
19. Byrne C, Smart CR, Chu KC, Hartmann WH. Survival advantage differences by age. Evaluation of the extended follow-up of the Breast Cancer Detection Demonstration Project. Cancer 1994:74(1 Suppl):301-10.
20. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9.
21. International Classification of Diseases for Oncology. Geneva (Switzerland): World Health Organization; 1976.
22. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34: 541-54.
23. Pepe MS, Mori M, Kaplan-Meier. marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993;12:737-51.
24. Gaynor JJ, Feuer EJ, Tan CC, Wu DH. Little CR, Straus DJ, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
25. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames (IA): The Iowa State University Press; 1967.
26. Burch JC, Byrd BF, Vaughn WK, Results of estrogen treatment in one thousand hysterectomized women for 14318 years. In: van Keep PA, Greenblatt RB, Albeaux-Fernet M, editors. Consensus on Menopausal Research. Lancaster (U.K.): MTP Press Ltd.: 1976. p. 164-9.
27. Gambrell RD Jr. Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 1984;150:119-32.
28. Aalen OO. Effects of frailty in survival analysis. Stat Methods Med Res 1994;3: 227-43.
29. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997; 47:28-51.
30. Donegan WL. Prognostic factors. Stage and receptor status in breast cancer. Cancer 1992; 70(6 Suppl): 1755-64.
31. Nesto RW, Cady B, Oberfield RA, Pazianos AG, Salzman FA. Rebound response after estrogen therapy for metastatic breast cancer. Cancer 1976;38:1834-7.